From the Journals

PCV13 vaccination safe, effective in 6- to 17-year-olds


 

FROM PEDIATRIC INFECTIOUS DISEASE JOURNAL

Positive immunogenicity results and lack of adverse events with receipt of the 13-valent pneumococcal conjugate vaccine by 200 children and adolescents in India supports extension of the indication to that population, reported Sharad Agarkhedkar, MD, of the Padmashree Dr. D. Y. Patil Medical College in Pune, India, and associates.

A picture of vaccines and a syringe DesignPics/Thinkstock

In an open-label study of 200 children and adolescents who received PCV13, 113 were 6 years to less than 10 years of age and 87 were aged 10-17 years; 54% were female. Antibody-mediated opsonophagocytic activity geometric mean titers were significantly higher for all vaccine serotypes 1 month after vaccination with PCV13, and there was no significant difference in psonophagocytic activity geometric mean titers between the two age groups. Immune responses after PCV13 vaccination were similar for the majority of serotypes in the study and in a U.S. study, the investigators said.

There were no acute reactions within 20 minutes of immunization. No adverse effects or severe adverse effects were recalled by caregivers who were questioned by the investigators 28-42 days following vaccination.

Read more in the Pediatric Infectious Diseases Journal (2017 Nov 1;36[11]:e282-5. doi: 10.1097/INF.0000000000001695).